Fluconazole for ketoconazole-resistant oropharyngeal candidiasis in HIV-1 infected patients.
The efficacy of fluconazole in doses ranging from 50 to 200 mg/day in controlling oropharyngeal candidiasis was retrospectively evaluated in 16 consecutive HIV-1-infected patients. 13 patients received fluconazole due to failure of treatment with ketoconazole, and among these 11 (84%) initially showed complete or partial remission of oropharyngeal candidiasis. 3 (27%) of these subsequently developed failure of treatment within a median observation period of 38 days. No major toxicities were observed. Fluconazole appears promising in the therapy of ketoconazole-resistant candidiasis.
Thorsen
S
S
Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Denmark.
Mathiesen
L R
LR
D000328:Adult; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D015725:Fluconazole; D007654:Ketoconazole